IVERIC bio, Inc. Common Stock
ISEE
ISEE was delisted on the 10th of July, 2023.
149 hedge funds and large institutions have $1.68B invested in IVERIC bio, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 61 increasing their positions, 33 reducing their positions, and 18 closing their positions.
212% more capital invested
Capital invested by funds: $537M → $1.68B (+$1.14B)
117% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 18
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
100% more call options, than puts
Call options by funds: $55.9M | Put options by funds: $28M
85% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 33
16% more funds holding
Funds holding: 128 → 149 (+21)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.9M |
| 2 |
PA
Perceptive Advisors
New York
|
+$31.4M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$29.4M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$22.7M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$18.7M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$16.1M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$15.8M |
| 4 |
DM
Deerfield Management
New York
|
-$9.83M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$8.87M |
ISEE Hedge Fund Activity: Q3 2021 in Review
149 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in IVERIC bio, Inc. Common Stock (ISEE) for Q3 2021, worth a combined $1.68B — up 212% from $537M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ISEE positions and 18 closed out — a net gain of 21 holders — while 61 added to existing stakes and 33 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $31.9M. The largest seller was Soleus Capital Management, cutting an estimated $18.7M.
- 149 institutional investors held IVERIC bio, Inc. Common Stock (ISEE) as of Q3 2021, up from 128 in Q2 2021.
- Funds reported $1.68B of IVERIC bio, Inc. Common Stock stock for Q3 2021, up 212% quarter-over-quarter.
- 39 funds opened new IVERIC bio, Inc. Common Stock positions in Q3 2021 and 18 closed out, a net change of +21 holders.
- The largest IVERIC bio, Inc. Common Stock buyer in Q3 2021 was T. Rowe Price Associates, an estimated $31.9M added.
- The largest IVERIC bio, Inc. Common Stock seller in Q3 2021 was Soleus Capital Management, an estimated $18.7M sold.
Based on aggregated 13F filings for Q3 2021.